BAL PHARMA LTD. - 524824 - Un-Audited Financial Results For The Quarter Ended 30.06.2022.
Board of Directors of the Company at their meeting held on 11.08.2022 has inter alia taken on record and approved the Un-audited financial results of the Company for the quarter ended 30.06.2022. Financial results along with the limited review reports issued by the statutory auditors of the Company are enclosed. BAL PHARMA LTD. - 524824 - Board Meeting Outcome for Outcome Of The Board Meeting
Board of Directors of the Company has inter alia taken on record and approved the un-audited financial results ( stand alone & consolidated ) of the Company for the quarter ended 30.06.2022. BAL PHARMA LTD. - 524824 - Board Meeting Intimation for Unaudited Financial Results
BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2022 ,inter alia, to consider and approve Unaudited financial results for the quarter ended 30.06.2022. BAL PHARMA LTD. - 524824 - Book Closure Intimation
Register of Members and Share Transfer books of the Company will remain closed from 15th September 2022 to 19th September 2022 ( both days inclusive) to ascertain the entitlement of dividend and for the 35th Annual General Meeting of the Company scheduled to be held on 19.09.2022, i.e on Monday. BAL PHARMA LTD. - 524824 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Based on the certificate's received from our R&T agents i.e TSR Darashaw Pvt Ltd, we would like to confirm that the details of securities dematerialized / rematerialized during the quarter ended on 30.06.2022 have been furnished to all the stock exchanges where the equity shares of the Company are listed, within the prescribed time limit. The Share certificates received for dematerialization, if any has been mutilated and cancelled after due verification and the name of the depository has been substituted in the records as registered owner, within 15 days of the receipt of the BAL PHARMA LTD. - 524824 - Statement Of Investor Complaints For The Quarter Ended June 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- GRemgarajanDesignation :- Chief Financial Officer BAL PHARMA LTD. - 524824 - Closure of Trading Window
Pursuant to the Code of conduct of the Company and as per the amended provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015, we wish to inform the exchange that the trading window for dealing with the securities of the Company on the designated employees and their relatives will be closed from 1st July 2022 and up to 48 hours of the declaration of the unaudited financial results of the Company, for the quarter ended 30/06/2022. The date of the Board meeting for declaration of the unaudited financial results, will be intimated to the exchange in due course. BAL PHARMA LTD. - 524824 - Disclosure Of Related Party Transactions 31.03.2022
Disclosure of Statement of Related Party Transactions for the half year ended 31.03.2022. BAL PHARMA LTD. - 524824 - Declaration Of Unmodified Opinion Audited Financial Results
Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare and confirm that the Statutory Auditors of the Company viz. NSVM & Associates, Chartered Accountants, having membership # 010072S have issued audit report with Unmodified opinion on audited Standalone and Consolidated Financial Statements of the Company, for the quarter and year ended March 31, 2022. The declaration of unmodified opinion was confirmed by the auditors in their audit report and the same was submitted to the exchanges vide our submission dated 30.05.2022. BAL PHARMA LTD. - 524824 - Announcement under Regulation 30 (LODR)-Newspaper Publication
We are submitting to the exchange newspaper advertisements of Audited financial results of the Company for the quarter and financial year ended 31/03/2022, published in Financial Express (English) and Sanjay vani (Kannada), on 01st June 2022.